SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent complication of end stage renal disease (ESRD). The Phase 1 study was a double-blind, randomized, placebo-controlled, rising single intravenous (IV) dose study to assess safety and tolerability of KAI-4169 in healthy male volunteers. Preliminary data from the study demonstrated KAI-4169 to be safe and well-tolerated and have confirmed the potency and activity of KAI-4169 by demonstrating dose-dependent reductions in parathyroid hormone and serum calcium levels. KAI plans to begin recruitment in a Phase 1b study in patients with ESRD and SHPT this quarter.
